Figure 5.

PET imaging using [⁸⁹Zr]Zr-DFO-KN035 before and after anti-PD-1 therapy of a patient (Case No.3) with PD-L1-positive lung cancer. (A) MIP image of the patient acquired with the [¹⁸F]FDG tracer at 1 h before combined therapy including the anti-PD-1 drug sintilimab. (B) MIP image of the same patient obtained by using the molecular-imaging tracer [⁸⁹Zr]Zr-DFO-KN035 at 56 h before anti-PD-1 treatment. (C) MIP image of the same patient obtained by using the molecular-imaging tracer [⁸⁹Zr]Zr-DFO-KN035 at 51 h after anti-PD-1 treatment. The images show the reduction in radioactive uptake in and shrinkage of the cancer focus. Two cycles of treatment, 2 months.